QALY weights for diabetic retinopathy - A comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO

Value in Health

Volumn 15, Issue 3, 2012, Pages 475-484

  Heintz, Emelie ^a   Wiréhn, Ann Britt ^a   Peebo, Beatrice Bourghardt ^b   Rosenqvist, Ulf ^c   Levin, Lars Åke ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c Motala Hospital   (Sweden)

Author keywords

diabetes mellitus; diabetic retinopathy; EQ 5D; health utility index mark 3; NEI VFQ 25; QALY; time trade off; TTO; VAS

Indexed keywords

BLINDNESS; CONTROLLED STUDY; COST UTILITY ANALYSIS; DIABETIC RETINOPATHY; HEALTH UTILITIES INDEX MARK 3; HUMAN; INTERMETHOD COMPARISON; INTERVIEW; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; REVIEW; TIME TRADE OFF METHOD; VALIDITY; VISION; VISUAL ANALOG SCALE; VISUAL IMPAIRMENT;

EID: 84861141229     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.11.031     Document Type: Article

References (59)

1. National Institute for Health and Clinical Excellence Guide to the Methods of Technology Appraisal 2008 National Institute for Health and Clinical Excellence London
2. International Society for Pharmacoeconomics and Outcomes Research Pharmacoeconomic guidelines around the world http://www.ispor.org/peguidelines/ index.asp 2008 Accessed September 28, 2011
3. J. Von Neumann, O. Morgenstern Theory of Games and Economic Behaviour 1944 Princeton University Press Princeton, New Jersey
4. G.W. Torrance, W.H. Thomas, D.L. Sackett A utility maximization model for evaluation of health care programs Health Serv Res 7 1972 118 133
5. D.L. Patrick, J.W. Bush, M.M. Chen Methods for measuring levels of well-being for a health status index Health Serv Res 8 1973 228 245
6. D. Feeny, W. Furlong, G.W. Torrance Multiattribute and single-attribute utility functions for the health utilities index mark 3 system Med Care 40 2002 113 128
7. The EuroQol Group EuroQol - a new facility for the measurement of health-related quality of life Health Policy 16 1990 199 208
8. H. Sintonen The 15D instrument of health-related quality of life: properties and applications Ann Med 33 2001 328 336 (Pubitemid 32675373)
9. J. Brazier, J. Roberts, M. Deverill The estimation of a preference-based measure of health from the SF-36 J Health Econ 21 2002 271 292 (Pubitemid 34143147)
10. The Pharmaceutical Benefits Board General Guidelines for Economic Evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2) 2003 The Pharmaceutical Benefits Board Stockholm
11. C.M. McDonough, A.N. Tosteson Measuring preferences for cost-utility analysis: how choice of method may influence decision-making Pharmacoeconomics 25 2007 93 106 (Pubitemid 46175547)
12. J. Seymour, P. McNamee, A. Scott Shedding new light onto the ceiling and floor? A quantile regression approach to compare EQ-5D and SF-6D responses Health Econ 19 2010 683 696
13. J.A. Kopec, K.D. Willison A comparative review of four preference-weighted measures of health-related quality of life J Clin Epidemiol 56 2003 317 325 (Pubitemid 36593310)
14. M. Espallargues, C.J. Czoski-Murray, N.J. Bansback The impact of age-related macular degeneration on health status utility values Invest Ophthalmol Vis Sci 46 2005 4016 4023 (Pubitemid 44264600)
15. G.R. Barton, T.H. Sach, M. Doherty An assessment of the discriminative ability of the EQ-5D index, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions Eur J Health Econ 9 2008 237 249 (Pubitemid 351962397)
16. E.K. Fenwick, K. Pesudovs, G. Rees The impact of diabetic retinopathy: understanding the patient's perspective Br J Ophthalmol 95 2010 774 782
17. B.S. Lee, S.M. Kymes, R.F. Nease Jr The impact of anchor point on utilities for 5 common ophthalmic diseases Ophthalmology 115 2008 898 903 e4
18. S.M. Kymes, B.S. Lee Preference-based quality of life measures in people with visual impairment Optom Vis Sci 84 2007 809 816 (Pubitemid 47262992)
19. A.K. Sjolie, R. Klein, M. Porta Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial Lancet 372 2008 1385 1393
20. N. Chaturvedi, M. Porta, R. Klein Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials Lancet 372 2008 1394 1402
21. M. Mauer, B. Zinman, R. Gardiner Renal and retinal effects of enalapril and losartan in type 1 diabetes N Engl J Med 361 2009 40 51
22. A. Lloyd, B. Nafees, S. Gavriel Health utility values associated with diabetic retinopathy Diabet Med 25 2008 618 624 (Pubitemid 351590891)
23. N. Kontodimopoulos, E. Pappa, Z. Chadjiapostolou Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications Eur J Health Econ 13 2012 111 120 Epub 2010 Dec 5
24. N. Aoki, K. Dunn, T. Fukui Cost-effectiveness analysis of telemedicine to evaluate diabetic retinopathy in a prison population Diabetes Care 27 2004 1095 1101 (Pubitemid 38579772)
25. S. Vijan, T.P. Hofer, R.A. Hayward Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus JAMA 283 2000 889 896 (Pubitemid 30102129)
26. H. Zhou, D.J. Isaman, S. Messinger A computer simulation model of diabetes progression, quality of life, and cost Diabetes Care 28 2005 2856 2863 (Pubitemid 43942915)
27. M. Brandle, W.H. Herman The CORE diabetes model Curr Med Res Opin 20, Suppl. 1 2004 S1 S3
28. T.H. Tung, S.J. Chen, F.L. Lee A community-based study for the utility values associated with diabetic retinopathy among type 2 diabetics in Kinmen, Taiwan Diabetes Res Clin Pract 68 2005 265 273
29. Statistics Sweden Återstående livslängd efter kön och ålder http://www.ssd.scb.se/databaser/makro/MainTable.asp?yp= dddbbf&xu=96487001&omradekod=BE&omradetext=Befolkning&lang= 1&langdb=1 [Accessed November 12, 2008]
30. The EuroQol Group EQ-5D products September 28, 2011 http://www.euroqol. org/eq-5d/eq-5d-products.html [Accessed September 28, 2011]
31. HUInc HEALTH UTILITIES INC An Overview 2011 [Accessed September 28, 2011] http://www.healthutilities.com/
32. P. Dolan, C. Gudex, P. Kind A Social Tariff for EuroQol: Results from a UK General Population Survey Discussion Paper No. 138 1995 Centre for Health Economics, University of York York
33. C.M. Mangione, P.P. Lee, P.R. Gutierrez Development of the 25-item National Eye Institute Visual Function Questionnaire Arch Ophthalmol 119 2001 1050 1058 (Pubitemid 32652197)
34. P. Dolan, C. Gudex, P. Kind The time trade-off method: results from a general population study Health Econ 5 1996 141 154 (Pubitemid 126484860)
35. H. White A heteroscedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity Econometrica 48 1980 817 838
36. E.M. Pullenayegum, J.E. Tarride, F. Xie Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate? Value Health 13 2010 487 494
37. J. Neter Applied Linear Statistical Models (4th ed) 1996 Irwin Chicago, IL 1408
38. J. Brazier, M. Deverill A checklist for judging preference-based measures of health related quality of life: learning from psychometrics Health Econ 8 1999 41 51 (Pubitemid 29057354)
39. S. Petrou, J. Morrell, H. Spiby Assessing the empirical validity of alternative multi-attribute utility measures in the maternity context Health Qual Life Outcomes 7 2009 40
40. J.P. Grutters, M.A. Joore, F. van der Horst Choosing between measures: comparison of EQ-5D, HUI2 and HUI3 in persons with hearing complaints Qual Life Res 16 2007 1439 1449 (Pubitemid 47459877)
41. N. Luo, J.A. Johnson, J.W. Shaw Relative efficiency of the EQ-5D, HUI2, and HUI3 index scores in measuring health burden of chronic medical conditions in a population health survey in the United States Med Care 47 2009 53 60
42. S. Petrou, C. Hockley An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population Health Econ 14 2005 1169 1189 (Pubitemid 41645379)
43. C.A. Marra, J.C. Woolcott, J.A. Kopec A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis Soc Sci Med 60 2005 1571 1582 (Pubitemid 40126441)
44. P.M. Fayers, D. Machin Quality of Life Assessment, Analysis and Interpretation 2000 Wiley Chichester, UK
45. J. Cohen A power primer Psychol Bull 112 1992 155 159
46. B. Rosner Fundamentals of Biostatistics (6th ed.) 2006 Thomson-Brooks/Cole Belmont, CA
47. K. Burstrom, M. Johannesson, F. Diderichsen A comparison of individual and social time trade-off values for health states in the general population Health Policy 76 2006 359 370 (Pubitemid 46137849)
48. N. Zethraeus, M. Johannesson A comparison of patient and social tariff values derived from the time trade-off method Health Econ 8 1999 541 545 (Pubitemid 29462245)
49. D. Polsky, R.J. Willke, K. Scott A comparison of scoring weights for the EuroQol derived from patients and the general public Health Econ 10 2001 27 37
50. J. Brazier, J. Ratcliffe, J. Salomon Measuring and Valuing Health Benefits for Economic Evaluation 2007 Oxford University Press Oxford
51. M.F. Drummond, M.J. Sculpher, G.W. Torrance Methods for the Economic Evaluation of Health Care Programmes (3rd ed.) 2005 Oxford University Press Oxford
52. A.L. Childs Effect of order of administration of health-related quality of life interview instruments on responses Qual Life Res 14 2005 493 500 (Pubitemid 40576399)
53. E. McColl, M.P. Eccles, N.S. Rousseau From the generic to the condition-specific? Instrument order effects in quality of life assessment Med Care 41 2003 777 790
54. A.C. Rat, C. Baumann, S. Klein Effect of order of presentation of a generic and a specific health-related quality of life instrument in knee and hip osteoarthritis: a randomized study Osteoarthritis Cartilage 16 2008 429 435 (Pubitemid 351426267)
55. S. McPhail, P. Lane, T. Russell Telephone reliability of the Frenchay Activity Index and EQ-5D amongst older adults Health Qual Life Outcomes 7 2009 48
56. E.E. van Wijck, J.L. Bosch, M.G. Hunink Time-tradeoff values and standard-gamble utilities assessed during telephone interviews versus face-to-face interviews Med Decis Making 18 1998 400 405 (Pubitemid 28465281)
57. A.W. Wu, D.L. Jacobson, R.A. Berzon The effect of mode of administration on medical outcomes study health ratings and EuroQol scores in AIDS Qual Life Res 6 1997 3 10 (Pubitemid 27110089)
58. S.M. Szabo, K.M. Beusterien, A.M. Pleil Patient preferences for diabetic retinopathy health states Invest Ophthalmol Vis Sci 51 2010 3387 3394
59. C. McCabe, K. Claxton, A.J. Culyer The NICE cost-effectiveness threshold: what it is and what that means Pharmacoeconomics 26 2008 733 744